Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction

Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.Erectile dysfunction (ED) is one of the commonest disorders in adult males and affects 12-19% of men of reproductive age.Erectile dysfunction can be due to vasculogenic, neurogenic, hormonal, veno-occlusive, psychogenic and/or pharmacogenic factors. PRP is autologous plasma that has a platelet concentration above the concentrations typically found in whole blood and is derived from the patient's own blood (autologous) through a process of centrifugation. PDE5Is inhibit the enzyme phosphodiesterase-5 (PDE-5) leading to dilatation of the penile arteries leads to a more prolonged erection.

Inclusion Criteria: * Have a diagnosis of ED due to organic origin for at least 6 months prior to consent. * Sexually active in a stable, heterosexual relationship of more than three months duration. * Agree to attempt sexual intercourse at least 3 times per month for the duration of the study without being under the influence of alcohol or recreational drugs. * Agree to comply with all study related tests/procedures. * provide written informed consent. Exclusion Criteria: * Previous penile surgery of any kind (except circumcision ). * Previous history of penile fracture or priapism. * Psychogenic ED as determined by study investigator. * Anatomical (Peyronie's Disease or penile curvature that negatively influences sexual activity). * Patients using Intracavernosal Injection (ICI) for management of ED. * Patients with generalized polyneuropathy, or neurological conditions irrespective of cause, such as severe diabetes, multiple sclerosis or Parkinson's disease. * Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study. * Any history of significant psychiatric disease.